医药生物行业报告（2026.02.02-2026.02.06）：政策加快中药工业结构优化和转型升级，支持中药工业龙头企业发展

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. Innovative Drugs: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. Medical Devices: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. Traditional Chinese Medicine: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. AI in Healthcare: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].